Biolinq has raised $205.0M in total across 3 funding rounds.
Biolinq's investors include RiverVest, T1D Fund, Boehringer Ingelheim Venture Fund.
Biolinq is a medtech company developing wearable biosensors for metabolic health monitoring, starting with non-invasive intradermal glucose sensing for diabetes management.[1][3][6] Its flagship product, Biolinq Shine, is the first FDA-cleared fully autonomous, needle-free glucose sensor with an integrated display, tracking glucose alongside activity and sleep without requiring a phone or hypodermic needles.[4][6] Biolinq serves people with diabetes (especially Type 2) and those focused on metabolic health, solving pain points like invasive finger pricks or cumbersome continuous glucose monitors (CGMs) by offering real-time, contextual insights in a simple patch form.[3][4][6] The company has raised over $120 million, including a recent $58 million round, fueling clinical validation (>500,000 hours of data) and commercialization amid strong growth momentum.[4][5]
Biolinq was founded in 2012 in San Diego (initially as Electrozyme LLC in La Jolla, CA) by a team leveraging expertise in computational systems physiology, chemometrics, and solid-state biosensors.[1][2] The idea emerged from advancing electrochemical sensor paradigms for healthcare, wellness, sports, military, and environmental applications, evolving into a focus on intradermal biosensing for metabolic conditions like diabetes.[2] Early traction built through IP development, scientific validation, and partnerships, with pivotal moments including rebranding to Biolinq and recent FDA De Novo classification for Shine in 2025, alongside the $58 million funding led by Alpha Wave Ventures.[1][4]
Biolinq stands out in the crowded CGM market through patented intradermal technologies and user-centric design:
Biolinq rides the biowearables trend, transforming diabetes care from reactive fingersticks to proactive, real-time monitoring integrated with lifestyle data amid a $20B+ CGM market dominated by Dexcom and Abbott.[3][4] Timing aligns with rising metabolic health demands—driven by Type 2 diabetes prevalence, consumer wellness adoption, and FDA's De Novo nod establishing a new sensor category—fueled by semiconductor advances enabling ultra-small, scalable biosensors.[2][4][5] Market forces like AI-driven personalization and post-pandemic health tech investment favor Biolinq, positioning it to influence the ecosystem by expanding multi-biomarker wearables beyond glucose into wellness and beyond.[1][3]
Biolinq's FDA win and $58M raise signal commercialization acceleration, with Shine launching to capture share in non-invasive CGM for Type 2 diabetes and metabolic wellness.[4] Next steps likely include pivotal trials, multi-analyte expansions (e.g., lactate, electrolytes), and partnerships for verticals like sports and military, leveraging 500,000+ clinical hours.[2][5] Trends like AI analytics, semiconductor scaling, and biowearable convergence will amplify growth, potentially evolving Biolinq from diabetes disruptor to metabolic health platform leader—echoing its mission to unlock "an ocean of data within your skin" for empowered, precise care.[5][6]
Biolinq has raised $205.0M across 3 funding rounds. Most recently, it raised $100.0M Series C in March 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2025 | $100.0M Series C | RiverVest, T1D Fund | |
| Nov 1, 2021 | $100.0M Series B | Boehringer Ingelheim Venture Fund, RiverVest, T1D Fund | |
| Mar 1, 2019 | $5.0M Series A | Boehringer Ingelheim Venture Fund, T1D Fund |
